Veterinary Therapeutics最新文献

In the past 5 years, the incidence of canine skin infections caused by resistant strains of Staphylococcus (pseud)intermedius has increased. Many older antibiotics are used to treat these infections because the sensitivity can be demonstrated in vitro. Additionally, many of these older drugs are efficacious and unlikely to induce multidrug resistance. More than a decade ago, the antibiotic tylosin tartrate was reported to be efficacious in vitro and in vivo against Staphylococcus intermedius. The purpose of this study was to determine whether S. (pseud)intermedius isolated from untreated pyoderma cases at veterinary referral centers across the United States are sensitive in vitro to this antibiotic. Minimum inhibitory concentrations for tylosin tartrate and other commonly used antibiotics were determined for 103 isolates. Most (82.61%) of the isolates not exposed to antibiotics in the 3 months before submission were sensitive to tylosin tartrate. These findings suggest that tylosin tartrate warrants further study as a first-line option for the treatment of dogs initially presenting with pyoderma.

Although probiotics are generally considered to be safe, their increasingly widespread use warrants better understanding of their risks in companion animals. This study evaluated the safety and tolerance of dietary supplementation with a canine-derived probiotic, Bifidobacterium animalis strain AHC7 (Prostora, Procter & Gamble Pet Care), fed to growing beagles beginning at approximately 6 months of age (11 males; 9 females). Probiotic B. animalis AHC7 administered orally once per day at a dose of up to 5 x 1010 colony-forming units for at least 12 consecutive weeks was well tolerated with no safety concerns.

Stem cells and their potential therapeutic uses in human and veterinary medicine have generated considerable interest. These cells have a number of potentially unique immunologic properties; most notable are their reported regenerative and antiinflammatory capabilities. The aim of this prospective pilot study was to evaluate the efficacy of intravenously administered autogenous adipose-derived mesenchymal stem cells (AD-MSCs) in the treatment of canine atopic dermatitis. AD-MSCs administered intravenously at a dose of 1.3 million cells/kg did not significantly reduce the clinical signs of canine atopic dermatitis or the owner-assessed pruritus level.

Twelve cats were vaccinated at 8 and 11 weeks of age with a commercially available inactivated FeLV vaccine (Nobivac FeLV, Intervet/Schering-Plough Animal Health). Eleven cats served as age-matched, placebo-vaccinated controls. All cats were kept in isolation for 2 years after vaccination and were then challenged with virulent FeLV to evaluate vaccine efficacy and duration of immunity. Cats were monitored for 12 weeks after challenge for development of persistent viremia using a commercial FeLV p27 ELISA. Persistent viremia developed in all 11 (100%) of the control cats, whereas 10 of 12 (83%) vaccinated cats were fully protected from persistent viremia following challenge. The results demonstrate that the vaccine used in this study protects cats from persistent FeLV viremia for at least 2 years after vaccination.

This pilot study evaluated protection of an equine autogenous bacterin-toxoid vaccine against Corynebacterium pseudotuberculosis infection. Twenty-four BALB/c mice were inoculated with two doses of bacterin-toxoid vaccine or two injections of a placebo. Clinical, microbiologic, and pathologic outcomes were assessed after intradermal infection with one of two equine-origin C. pseudotuberculosis strains. Mice receiving bacterin-toxoid from fast-growing C. pseudotuberculosis showed significant protection from challenge infection, as evidenced by a higher survival rate, fewer gross and histopathologic lesions, and lower bacterial levels on culture. Successful protection via a vaccine against equine internal abscesses might provide supplementary management options against an important, potentially fatal disease.

Methimazole (thiamazole) is an antithyroid drug commonly used to treat feline hyperthyroidism. It is routinely given twice daily. Carbimazole is a methimazole derivative that is rapidly metabolized to methimazole in vivo. A controlled-release tablet for once-daily carbimazole therapy has recently been developed in an attempt to improve compliance during medical management of feline hyperthyroidism. The results of a crossover study in six cats suggest that the pharmacokinetics of methimazole with a single dose of this controlled-release tablet may be similar to those with a single dose of a sugar-coated methimazole tablet when the two drugs are given at an equimolar dose. The mean half-lives were nearly identical (3.12 hours, sugar-coated methimazole tablets; 3.28 hours, controlled-release carbimazole tablets). The serum concentrations of methimazole at 24 hours were 21.7 ± 28.9 ng/mL in the cats treated with 5-mg sugar-coated methimazole tablets and 28.7 ± 37 ng/mL in the cats treated with 10-mg carbimazole tablets (which provide approximately 25% more methimazole after conversion to the active metabolite).

This study determined the antimicrobial activity of tulathromycin against Rhodococcus equi in vitro. Ninety-eight virulent isolates of R. equi from equine clinical cases were examined, of which 20 isolates were macrolide resistant. A custom 96-well antimicrobial susceptibility testing plate was used, allowing 14 additional antimicrobials to be tested against R. equi. Isolates were cultured with various concentrations of antimicrobials, and minimal inhibitory concentration (MIC) values were determined. Tulathromycin was found to have poor activity in vitro against R. equi isolates susceptible or resistant to macrolides, with MIC50 and MIC90 values >64 ug/mL for all isolates. MIC values for other macrolides tested were similar to previously published data.

This study investigated the effects on cardiovascular parameters, if any, of a commercially available combination of metaflumizone and amitraz administered to healthy, telemetered beagles that were subsequently sedated with dexmedetomidine. Dogs were sedated first without any pretreatment and then after pretreatment with metaflumizone and amitraz. Baseline values of all parameters were within normal limits for all dogs before the first anesthetic event. At 10 and 20 minutes after onset of sedation, oxygen saturation as measured by pulse oximetry was significantly higher for dogs that were pretreated with metaflumizone and amitraz. At all times after induction of sedation, blood pressure, heart rate, and baseline body temperature for dogs pretreated with metaflumizone and amitraz were not statistically different from when they were not pretreated. In conclusion, prior treatment with metaflumizone and amitraz did not influence the hemodynamic response to dexmedetomidine in telemetered dogs.

Fleas cause significant discomfort to pet cats and distress to their owners and are also vectors of disease severe infestations can cause anemia or flea allergy dermatitis and can lead to infections with Dipylidium caninum and Bartonella henselae. Rapid flea kill is an important feature of flea preventives. The efficacy of dinotefuran (Vectra for Cats and Kittens, Summit VetPharm) was compared with that of imidacloprid (Advantage, Bayer Animal Health) against Ctenocephalides felis when applied topically once on day 0. Cats were infested with 100 (+-3) C. felis on study days -1, 8, 15, 22, and 29. Live fleas were counted on study days 0 (2, 6, and 12 hours after treatment), 9, 16, 23, 29 (2, 6, and 12 hours after infestation), and 30. Cats treated with dinotefuran had significantly (P less than .05) fewer fleas than the control cats at all posttreatment examinations except day 29 at 2 hours after infestation and significantly (P less than .05) fewel fleas than cats treated with imidacloprid on days 0 (2 hours after treatment), 9, 16, 23, 29 (6 and 12 hours after infestation), and 30.

Amblyomma americanum (lone star tick) and Amblyomma maculatum (Gulf Coast tick) are important disease vectors for both dogs and humans. This article describes two studies conducted to evaluate the efficacy of a new topical spot-on ectoparasiticide containing dinotefuran, permethrin, and pyriproxyfen (Vectra 3D, Summit VetPharm) against A. maculatum and A. americanum in dogs. Dogs were treated on day 0 and infested on days -1, 7, 14, 21, and 28 with approximately 40 ticks each day. Live tick counts were determined 48 hours after infestation. Treatment with Vectra 3D resulted in a significant reduction in A. maculatum tick counts throughout the study period. For A. americanum, there was a significant reduction in tick counts from study day 9 onward. The results of this study indicate that Vectra 3D can be used as an effective part of an overall tick- and vector-borne disease control strategy on dogs when used monthly.